Simulations Plus, Inc. (Nasdaq:SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has received an order from the U.S. Food and Drug Administration (FDA) for a 15-user license to its ADMET Predictor^® software suite. The purchase was made by the Center for Tobacco Products to support research projects aimed at informing regulatory decision making.

John DiBella, Lancaster division president for Simulations Plus, said: “For many years, the FDA has utilized our software across various departments, including the Office of Clinical Pharmacology, Office of Generic Drugs, and Office of Pharmaceutical Quality. We are thrilled to now see the Center for Tobacco Products incorporate our machine learning technology to support their risk assessment activities as they evaluate tobacco products and ingredients. We look forward to interactions with the FDA staff to understand model performance on their chemicals and identify future advances to ADMET Predictor’s functionality and workflow.”

Views expressed in this press release do not necessarily reflect the official policies of the Department of Health and Human Services; nor does any mention of trade names, commercial practices, or organizations imply endorsement by the United States Government.